IL220365A - Humanized fcγr mice and methods of screening an agent comprising an fc region of a human antibody - Google Patents

Humanized fcγr mice and methods of screening an agent comprising an fc region of a human antibody

Info

Publication number
IL220365A
IL220365A IL220365A IL22036512A IL220365A IL 220365 A IL220365 A IL 220365A IL 220365 A IL220365 A IL 220365A IL 22036512 A IL22036512 A IL 22036512A IL 220365 A IL220365 A IL 220365A
Authority
IL
Israel
Prior art keywords
mice
human
region
methods
scanning
Prior art date
Application number
IL220365A
Other languages
English (en)
Hebrew (he)
Other versions
IL220365A0 (en
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43601078&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL220365(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of IL220365A0 publication Critical patent/IL220365A0/en
Publication of IL220365A publication Critical patent/IL220365A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0387—Animal model for diseases of the immune system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Environmental Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • General Physics & Mathematics (AREA)
  • Endocrinology (AREA)
IL220365A 2009-12-21 2012-06-13 Humanized fcγr mice and methods of screening an agent comprising an fc region of a human antibody IL220365A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28856209P 2009-12-21 2009-12-21
PCT/US2010/060925 WO2011084664A1 (en) 2009-12-21 2010-12-17 HUMANIZED FCγ R MICE

Publications (2)

Publication Number Publication Date
IL220365A0 IL220365A0 (en) 2012-08-30
IL220365A true IL220365A (en) 2016-11-30

Family

ID=43601078

Family Applications (4)

Application Number Title Priority Date Filing Date
IL220365A IL220365A (en) 2009-12-21 2012-06-13 Humanized fcγr mice and methods of screening an agent comprising an fc region of a human antibody
IL242719A IL242719A (en) 2009-12-21 2015-11-23 Mice with human fcγr
IL261257A IL261257B (en) 2009-12-21 2018-08-20 Humanized fc㚚šššššr mice
IL271083A IL271083A (en) 2009-12-21 2019-12-01 Humanized fcgammar mice

Family Applications After (3)

Application Number Title Priority Date Filing Date
IL242719A IL242719A (en) 2009-12-21 2015-11-23 Mice with human fcγr
IL261257A IL261257B (en) 2009-12-21 2018-08-20 Humanized fc㚚šššššr mice
IL271083A IL271083A (en) 2009-12-21 2019-12-01 Humanized fcgammar mice

Country Status (27)

Country Link
US (9) US8658154B2 (enExample)
EP (4) EP3336102A3 (enExample)
JP (4) JP5595517B2 (enExample)
KR (4) KR102092744B1 (enExample)
CN (2) CN104232589B (enExample)
AU (3) AU2010339863B2 (enExample)
CA (2) CA3000246C (enExample)
CY (1) CY1120316T1 (enExample)
DK (2) DK2516457T3 (enExample)
ES (2) ES3062012T3 (enExample)
FI (1) FI3498730T3 (enExample)
HK (1) HK1257001A1 (enExample)
HR (2) HRP20260349T1 (enExample)
HU (1) HUE038684T2 (enExample)
IL (4) IL220365A (enExample)
LT (2) LT2516457T (enExample)
MY (1) MY156743A (enExample)
NO (1) NO2516457T3 (enExample)
PL (2) PL3498730T3 (enExample)
PT (2) PT2516457T (enExample)
RS (2) RS67844B1 (enExample)
RU (1) RU2549695C2 (enExample)
SG (3) SG10201408415PA (enExample)
SI (2) SI2516457T1 (enExample)
SM (2) SMT201800296T1 (enExample)
TR (1) TR201808011T4 (enExample)
WO (1) WO2011084664A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2516457T3 (enExample) 2009-12-21 2018-08-11
PL2818478T3 (pl) 2011-10-28 2017-09-29 Regeneron Pharmaceuticals, Inc. Humanizowane il-6 i receptor il-6
JP2014532399A (ja) * 2011-11-01 2014-12-08 ロシュ グリクアート アーゲー インビボａｄｃｃモデル
ES2884598T3 (es) * 2012-11-05 2021-12-10 Regeneron Pharma Animales no humanos modificados genéticamente y métodos de uso de los mismos
ES2844174T3 (es) 2013-09-18 2021-07-21 Kymab Ltd Métodos, células y organismos
AU2014337526B2 (en) 2013-10-15 2020-09-10 Regeneron Pharmaceuticals, Inc. Humanized IL-15 animals
WO2015088643A1 (en) 2013-12-11 2015-06-18 Regeneron Pharmaceuticals, Inc. Methods and compositions for the targeted modification of a genome
CN106255410B (zh) * 2014-03-21 2020-01-10 瑞泽恩制药公司 产生单结构域结合蛋白的非人动物
RU2700484C2 (ru) * 2014-04-08 2019-09-17 Регенерон Фармасьютикалз, Инк. Не относящиеся к человеку животные, имеющие гуманизированные fc-гамма-рецепторы
AU2015266841C1 (en) 2014-05-30 2018-06-07 Regeneron Pharmaceuticals, Inc. Humanized dipeptidyl peptidase IV (DPP4) animals
EP3808775B1 (en) * 2014-12-09 2024-04-17 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized cluster of differentiation 274 gene
PT3282835T (pt) * 2015-04-13 2023-07-25 Univ Yale Ratinhos knockin de sirpa-il15 humanizadas e métodos de utilização dos mesmos
WO2016175285A1 (ja) * 2015-04-30 2016-11-03 株式会社特殊免疫研究所 ヒト特定分子およびヒトＦｃγ受容体ファミリーを発現するトランスジェニック非ヒト動物
US20170332610A1 (en) 2016-05-20 2017-11-23 Regeneron Pharmaceuticals, Inc. Methods for breaking immunological tolerance using multiple guide rnas
US11879014B2 (en) * 2017-03-17 2024-01-23 Tusk Therapeutics Ltd. Method of treating cancer or depleting regulatory T cells in a subject by administering a human IGG1 anti-CD25 antibody
WO2019190990A1 (en) 2018-03-26 2019-10-03 Regeneron Pharmaceuticals, Inc. Humanized rodents for testing therapeutic agents
JP6935383B2 (ja) * 2018-09-27 2021-09-15 公益財団法人実験動物中央研究所 免疫不全マウス
EP3861854B1 (en) * 2018-09-27 2025-01-22 Central Institute for Experimental Medicine and Life Science Immunodeficient mouse
SG11202107589PA (en) 2019-02-22 2021-08-30 Regeneron Pharma Rodents having genetically modified sodium channels and methods of use thereof
US20220192166A1 (en) * 2019-03-28 2022-06-23 Central Institute For Experimental Animals Immunodeficient rodent
AU2021400584A1 (en) * 2020-12-16 2023-06-29 Regeneron Pharmaceuticals, Inc. Mice expressing humanized fc alpha receptors
EP4287828A4 (en) * 2021-02-02 2025-01-15 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Genetically modified non-human animal with human or chimeric fcrn
WO2026096736A1 (en) 2024-10-31 2026-05-07 Regeneron Pharmaceuticals, Inc. Rodents expressing humanized polymeric immunoglobulin receptor

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989011490A1 (en) * 1988-05-27 1989-11-30 Schering Biotech Corporation HUMAN Fcgamma RECEPTOR III
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5258359A (en) * 1991-08-02 1993-11-02 Monsanto Company Glyphosant-containing herbicidal compositions comprising acetylenic diol rainfastness enhancing agents
WO1994006908A1 (en) 1992-09-11 1994-03-31 The Regents Of The University Of California Transgenic non-human animals having targeted lymphocyte transduction genes
US5877396A (en) * 1993-04-23 1999-03-02 Sloan Kettering Institute For Cancer Research Mice mutant for functional Fc receptors and method of treating autoimmune diseases
US6111166A (en) * 1994-09-19 2000-08-29 Medarex, Incorporated Transgenic mice expressing human Fcα and β receptors
ATE549918T1 (de) 1996-12-03 2012-04-15 Amgen Fremont Inc Menschliche antikörper, die ausdrücklich menschliches tnf alpha binden
US5899312A (en) * 1997-07-22 1999-05-04 Lucent Technologies Inc Anti-fraud string grabbing device
US6676927B1 (en) * 1999-01-20 2004-01-13 The Rockefeller University Animal model and methods for its use in the selection of cytotoxic antibodies
FR2807767B1 (fr) * 2000-04-12 2005-01-14 Lab Francais Du Fractionnement Anticorps monoclonaux anti-d
CA2399940A1 (en) 2000-04-13 2001-10-25 The Rockefeller University Enhancement of antibody-mediated immune responses
CN101498731A (zh) * 2000-05-18 2009-08-05 日本烟草产业株式会社 抗协同刺激信号转导分子ailim的人单克隆抗体及其药物用途
US7413031B2 (en) 2000-07-18 2008-08-19 The Charles Machine Works, Inc. Apparatus and method for maintaining control of a drilling machine
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
FR2822161B1 (fr) 2001-03-15 2003-09-19 Genoway Cellule et animal transgenique modelisant les reponses humaines allergiques mediees par les ige, et leurs utilisations
JP4653915B2 (ja) * 2001-10-29 2011-03-16 独立行政法人科学技術振興機構 全身性エリテマトーデスモデル非ヒト動物
US20040132101A1 (en) * 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
AU2003233246B2 (en) 2002-06-07 2008-04-10 The Macfarlane Burnet Institute For Medical Research And Public Health Ltd FcyRIIa transgenic animal model for autoimmune disease
JP2004147535A (ja) * 2002-10-29 2004-05-27 Japan Science & Technology Agency ギラン・バレー症候群及び／又はフィッシャー症候群発症モデル非ヒト動物
JP2006517096A (ja) 2002-12-16 2006-07-20 ジェネンテック・インコーポレーテッド ヒトｃｄ２０を発現するトランスジェニックマウス
FR2858235B1 (fr) * 2003-07-31 2006-02-17 Lab Francais Du Fractionnement Utilisation d'anticorps optimises en adcc pour traiter les patients faibles repondeurs
US20070148170A1 (en) * 2005-10-03 2007-06-28 Desjarlais John R Fc Variants With Optimized Fc Receptor Binding Properties
EP1706424B1 (en) * 2004-01-12 2009-07-22 Applied Molecular Evolution, Inc. Fc region variants
WO2006044962A1 (en) 2004-10-19 2006-04-27 Regeneron Pharmaceuticals, Inc. Method for generating an animal homozygous for a genetic modification
EP1999470A4 (en) 2006-03-10 2009-08-19 Macrogenics Inc IDENTIFICATION AND GENETIC MODIFICATION OF ANTIBODIES WITH HEAVY CHAINS OF VARIANTS AND METHODS OF USE THEREOF
US20080003225A1 (en) 2006-06-29 2008-01-03 Henri Vie Method for enhancing the antibody-dependent cellular cytotoxicity (ADCC) and uses of T cells expressing CD16 receptors
JP5401314B2 (ja) * 2006-09-08 2014-01-29 メディミューン，エルエルシー ヒト化抗ｃｄ１９抗体ならびに癌、移植および自己免疫疾患の治療におけるその使用
HU0700534D0 (en) * 2006-11-24 2007-10-29 Mezoegazdasagi Biotechnologiai Transgenic animal with enhanced immune response and method for the preparation thereof
BRPI0813985B1 (pt) 2007-07-31 2022-05-10 Regeneron Pharmaceuticals, Inc Anticorpos humanos ou fragmentos de ligação a antígenos, composição farmacêutica dos mesmos e método para produzir um anticorpo anti-cd20 humana ou fragmento de ligação a antígeno de um anticorpo
AU2008335178A1 (en) * 2007-12-10 2009-06-18 Ablexis Llc Methods for sequential replacement of targeted region by homologous recombination
TWI476280B (zh) 2008-03-07 2015-03-11 Regeneron Pharma 來自二倍體宿主胚胎注射之ｅｓ－細胞衍生的老鼠
WO2010010549A2 (en) * 2008-07-23 2010-01-28 Rappaport Family Institute For Research In The Medical Sciences Methods of altering peripheral b cell populations and uses thereof
NO2516457T3 (enExample) 2009-12-21 2018-08-11
US8883496B2 (en) * 2009-12-21 2014-11-11 Regeneron Phamaceuticals, Inc. Humanized FcgR mice

Also Published As

Publication number Publication date
US20240424145A1 (en) 2024-12-26
KR20190045404A (ko) 2019-05-02
JP2014132909A (ja) 2014-07-24
IL242719A (en) 2017-09-28
SMT201800296T1 (it) 2018-07-17
RU2012131296A (ru) 2014-01-27
MY156743A (en) 2016-03-31
KR102092744B1 (ko) 2020-03-24
KR20200033981A (ko) 2020-03-30
US20200061213A1 (en) 2020-02-27
US20150313195A1 (en) 2015-11-05
EP4706388A2 (en) 2026-03-11
SI3498730T1 (sl) 2026-03-31
US8658853B2 (en) 2014-02-25
HRP20180911T1 (hr) 2018-07-13
US12036288B2 (en) 2024-07-16
SG10202011814TA (en) 2021-01-28
US20140154701A1 (en) 2014-06-05
AU2010339863A1 (en) 2012-07-12
JP5891259B2 (ja) 2016-03-22
CA2784953C (en) 2018-05-22
KR101862277B1 (ko) 2018-06-01
KR20180058860A (ko) 2018-06-01
US8658154B2 (en) 2014-02-25
CA3000246A1 (en) 2011-07-14
EP3498730A1 (en) 2019-06-19
RS67844B1 (sr) 2026-03-31
EP2516457A1 (en) 2012-10-31
KR20120102138A (ko) 2012-09-17
HUE038684T2 (hu) 2018-11-28
CY1120316T1 (el) 2019-07-10
CN102762590A (zh) 2012-10-31
AU2010339863B2 (en) 2014-07-17
EP2516457B9 (en) 2021-09-29
US20120260357A1 (en) 2012-10-11
US20140157445A1 (en) 2014-06-05
IL261257A (en) 2018-10-31
CA2784953A1 (en) 2011-07-14
RU2549695C2 (ru) 2015-04-27
US20110154512A1 (en) 2011-06-23
AU2014210646A1 (en) 2014-08-28
SG10201408415PA (en) 2015-01-29
ES2671188T3 (es) 2018-06-05
AU2014210646B2 (en) 2016-06-23
SI2516457T1 (en) 2018-08-31
CN104232589A (zh) 2014-12-24
RS57280B1 (sr) 2018-08-31
JP5595517B2 (ja) 2014-09-24
CA3000246C (en) 2021-05-25
EP3498730B1 (en) 2026-01-28
AU2014210645A1 (en) 2014-08-28
DK2516457T3 (en) 2018-06-18
JP6073840B2 (ja) 2017-02-01
HK1257001A1 (en) 2019-10-11
US20210346522A1 (en) 2021-11-11
DK3498730T3 (da) 2026-02-23
FI3498730T3 (fi) 2026-03-12
AU2014210645B2 (en) 2016-05-19
PL2516457T3 (pl) 2018-08-31
SG181690A1 (en) 2012-07-30
HRP20260349T1 (hr) 2026-04-24
US9089599B2 (en) 2015-07-28
US9056130B2 (en) 2015-06-16
CN102762590B (zh) 2015-11-25
CN104232589B (zh) 2018-04-27
US20180015185A1 (en) 2018-01-18
EP3336102A2 (en) 2018-06-20
US10426848B2 (en) 2019-10-01
PL3498730T3 (pl) 2026-04-07
US11020495B2 (en) 2021-06-01
IL220365A0 (en) 2012-08-30
PT3498730T (pt) 2026-02-18
JP2016093201A (ja) 2016-05-26
SMT202600074T1 (it) 2026-03-09
WO2011084664A1 (en) 2011-07-14
KR101973524B1 (ko) 2019-09-02
KR102178064B1 (ko) 2020-11-12
PT2516457T (pt) 2018-06-12
LT3498730T (lt) 2026-03-25
JP2014209923A (ja) 2014-11-13
JP2013514778A (ja) 2013-05-02
TR201808011T4 (tr) 2018-06-21
US9687566B2 (en) 2017-06-27
IL261257B (en) 2019-12-31
NO2516457T3 (enExample) 2018-08-11
IL271083A (en) 2020-01-30
LT2516457T (lt) 2018-06-11
EP2516457B1 (en) 2018-03-14
EP3336102A3 (en) 2018-08-01
ES3062012T3 (en) 2026-04-08

Similar Documents

Publication Publication Date Title
SMT201600387B (it) MUTANTI DI Fc DI ANTICORPI CON ABLAZIONE DI FUNZIONI EFFETTRICI
IL271083A (en) Humanized fcgammar mice
IL257822A (en) Mice that make heavy chain antibodies
EP2495315A4 (en) HUMANIZED RECOMBINANT URICASE AND MUTANTS THEREOF
DK3674318T3 (da) Optimerede fc-varianter
EP4049535C0 (en) GENETICALLY MODIFIED MICE AND TRANSPLANTATION
BR112014018005A2 (pt) uso de complexo não covalente imobilizado e variante de região fc de isotipo igg1 humano
DK4339212T3 (da) Subkutan anti-her2-antistofformulering
BRPI1014404A2 (pt) cânula dotada de recurso de cânula e recurso de encaixe em sobreposição
EP2498853A4 (en) PATIENT INTERFACE AND ASPECTS OF IT
LT3725330T (lt) Stabilūs polipeptidų preparatai ir jų naudojimas
LT3248610T (lt) Fgf21 mutantai ir jų panaudojimas
EP2274666A4 (en) INTERACTIVE INPUT SYSTEM AND PEN TYPE TOOL FOR THIS SYSTEM
EP3421493C0 (en) MONOCLONAL ANTIBODIES AGAINST PROGASTRIN AND THEIR USES
EP2318438A4 (en) ANTI-P2X7 PEPTIDES AND EPITOPES
EP2207803A4 (en) Cd9-specific human antibodies
LT2552434T (lt) Peptidai ir jų naudojimas
BR112012003844A2 (pt) vacinas de pttv e diagnóstico
EP2405390A4 (en) Image search device and image search method
HRP20181973T1 (hr) Poboljšana anti humana fraktalkinska protutijela i njihova uporaba
DK2462237T3 (da) Fremgangsmåder til forbedring af rekombinant proteinekspression
ATE545328T1 (de) Mähfingeranordnung
IL214840A (en) Humanised antibodies with anti-tumour activity
DK2414523T3 (da) Mus med dendtritcelle-forstærket humaniseret immunsystem
EP2412721A4 (en) ANTI-KHV ANTIBODIES (KOÏ HERPESVIRUS) AND ANTIGEN ASSOCIATED

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed